Twenty-three genetically confirmed DMD boys with mean age 8.4 + 2.6 years were enrolled with age-matched healthy controls. Six-month follow-up 6MWT distance, NSAA score, and CMAP measures were obtained in 65% of patients (15/23). The baseline CMAP amplitudes in DMD patients were significantly reduced (p<0.001) compared to controls in all muscle groups tested with no significant changes in NSAA scores (p =0.70) or 6MWT distance (p = 0.25) from baseline to six months. A sub-group analysis of patients receiving chronic steroid therapy (n = 9) and in those initiating steroids at the time of enrollment (n = 4) showed significant increase only in the left (p = 0.02) and right fibular TA muscle CMAP amplitudes (p = 0.002).